Andrews Patricia S 4

What Happened Patricia S. Andrews, a director of Oncolytics Biotech Inc. (ONCY), was granted a derivative award covering 30,000 shares (stock options) on June 1, 2026. The grant required no cash payment at issuance (reported consideration $0). The exercise price for the options is equal to the closing price of Oncolytics’ common stock on the Nasdaq Capital Market on June 1, 2026.

Key Details

• Transaction date: 2026-06-01; Grant type: Award/derivative (stock options).
• Shares/units granted: 30,000 options; reported acquisition value: $0 at grant.
• Exercise price: set equal to Nasdaq closing price on 2026-06-01 (per footnote).
• Vesting: Options vest in three equal annual installments, first vesting on 2027-06-01, subject to continued service (per footnote).
• Shares/options owned after the transaction: not specified in the filing summary provided.
• Timeliness: Report filed 2026-06-03 for a 2026-06-01 grant—Form 4 appears timely (filed within the usual two-business-day window).

Context This filing documents a standard director equity grant—an option award that gives the holder the right to buy shares in the future at the stated exercise price. The award does not involve an immediate purchase or sale of shares and does not itself create proceeds until options are exercised (which would require paying the exercise price). Such grants are commonly used as compensation for board service and are not, by themselves, a direct market signal of insider buying or selling.